Rapport Therapeutics, Inc. Common Stock (RAPP)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 0 | 0 | 0 | 0 | 20 | 20 |
| Operating profit | $m | -125 | -154 | ||||||
| Net profit | $m | - | - | -11 | -35 | -78 | -111 | -137 | -198 |
| EPS reported | $ | -2.86 | -3.04 | ||||||
| Operating cashflow per share | $ | -1.86 | -2.04 | ||||||
| Capex per share | $ | 0.01 | 0.01 | ||||||
| FCF per share | $ | -1.88 | -2.05 | ||||||
| Free cash flow | $m | -88 | -97 | ||||||
| Net debt | $m | -482 | -436 | ||||||
| Book value equity | $m | 485 | 423 | ||||||
| Book value per share | $ | 10.32 | 8.91 | ||||||
| Number of shares | m | 46.98 | 47.47 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 2.94 | 3.37 | ||||||
| P/S LTM | x | 0.00 | 71.27 | ||||||
| P/FCF LTM | x | -16.18 | -14.67 | ||||||
| EV/EBITDA LTM | x | -11.16 | -9.34 | ||||||
| EV/Sales LTM | x | 0.00 | 110.72 | ||||||
| Earnings Yield LTM | % | -7.82% | -6.09% | ||||||
| FCF Yield | % | -6.18% | -6.82% | ||||||
| Quality | |||||||||
| ROE | % | -23.00% | -29.02% | ||||||
| ROIC | % | -25.21% | -35.45% | ||||||
| Operating margin | % | 0.00% | -7.68% | ||||||
| Gross margin | % | 0.00% | +100.00% | ||||||
| FCF/Sales | % | - | -485.75% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -7.67 | -9.61 | ||||||
| Net Debt/EBITDA | x | 0.33 | 0.36 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +0.61% | 0.00% | ||||||
| Net debt/Equity | x | -0.99 | -1.03 | ||||||
| Gross debt/equity | x | 0.02 | 0.02 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Rapport Therapeutics, Inc. Common Stock (RAPP)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free